For instance, anti-EphA2 mAbs (EA2 and B233) promoted EphA2 phosphorylation and degradation in cancer cells, and administration of EA2 mAb significantly decreased tumor growth in xenograft model [20]. Here, EPHA2 is linked to neoplasm.